Vertex Pharmaceuticals
VRTX
$515.02
-1.08%
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule and cell-based therapies for serious diseases, anchored by its cystic fibrosis franchise (Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi, Symdeko) and increasingly diversified into Casgevy gene editing for beta thalassemia and sickle-cell disease, Journavx for acute pain, Palsonify for acromegaly, plus pipeline assets in APOL1-mediated kidney disease, type 1 diabetes cell therapy, and povetacicept for IgA nephropathy. Vertex is the undisputed standard-of-care monopolist in cystic fibrosis globally, a rare position of pricing power and near-100% share that funds an aggressive, self-financed expansion into adjacent multibillion-dollar categories. The current investor debate centers on whether Vertex can convert its CF cash machine into a second and third growth engine — the roughly $10 billion Crinetics acquisition (hormone disorders/acromegaly), positive Phase II APOL1 kidney data, and the Journavx non-opioid pain launch — against a backdrop of a Q3 revenue beat and raised guidance offset by rising operating costs and a notable sequential earnings dip. Recent headlines frame the stock as a diversification story with pipeline catalysts (povetacicept, kidney disease interim data expected early 2027) rather than a pure CF compounder, and a competitor's CF trial failure has reinforced Vertex's defensive moat.…
VRTX
Vertex Pharmaceuticals
$515.02
Related headlines
Investment Opinion: Should I buy VRTX Today?
Rating: Buy (accumulate), with position sizing that respects binary pipeline risk. The core thesis is that Vertex's near-monopoly cystic fibrosis franchise — Trikafta/Kaftrio at $2.437B plus Alyftrek at $705.8M of Q3's $3.441B revenue — generates $3.202B of trailing free cash flow and funds a self-financed diversification into Crinetics/acromegaly, APOL1 kidney disease, povetacicept and Journavx without dilution, while 26 of 28 analysts rate the stock Buy with a $595.36 average target (~+10.5% from $538.60).
The supporting evidence is concrete: revenue grew 11.85% YoY to $3.441B with sequential expansion every quarter of 2026 ($2.987B → $3.334B → $3.441B), gross margin held at 84.71% and TTM net margin at 32.7%, and the balance sheet is fortress-grade with debt-to-equity of 0.109, a 2.90 current ratio and $4.989B of cash. Valuation is fair-to-slightly-rich rather than stretched — 29.32x trailing and 27.04x forward PE against a 21.18% ROE and 85.0% gross margin, with the forward multiple only ~8% below trailing, implying the market is not extrapolating aggressive acceleration. Momentum confirms the fundamental case: +23.26% over six months versus SPY's +2.13% (relative strength +21.13) and +8.04% over the past month against SPY's -2.26%, with the stock at ~80.8% of its $412.27–$568.67 range and a max drawdown of only 15.21%.
The risks that could invalidate this view are threefold: Q3 net margin collapsing to 18.99% from 32.99% in Q2 as R&D jumped to $1.321B, which would compress the multiple if it proves a new baseline rather than Crinetics integration cost; acute CF revenue concentration, where all non-CF products contributed just $130.5M; and binary pipeline readouts (APOL1 kidney interim data early 2027, povetacicept) that explain the $350–$725 target spread. This Buy would upgrade to a high-conviction add if Q4 operating margin recovers above ~30% and R&D normalizes below $1.1B, and would downgrade to Hold if revenue growth decelerates below 10% or operating margin stays below 22% for two consecutive quarters. Verdict: fairly valued to modestly undervalued relative to its quality and growth, with the premium versus the high-teens/low-20s sector PE justified by 85% gross margins and monopoly pricing power.
Sign up to view all
VRTX 12-Month Price Forecast
The forward view is constructive but tempered: Vertex is a high-quality compounder whose 27x forward PE is defensible against an 85% gross margin and 21.18% ROE, and whose $3.2B free cash flow self-funds the Crinetics, APOL1, povetacicept and Journavx expansion without dilution. The central swing factor is the Q3 margin reset — net margin fell to 18.99% from 32.99% as R&D rose to $1.321B — and whether that proves temporary integration cost or a new baseline; a Q4 recovery above 30% operating margin would justify the bull case toward $650–$725, while persistence below 22% would validate the $350 bear target. Analyst sentiment is stable rather than euphoric, with the modest +10.5% implied upside and 2x target spread signaling that diversification value is genuinely contested. I would upgrade to high confidence on a clean Q4 margin recovery plus positive kidney or povetacicept data, and downgrade to neutral if revenue growth slips below 10% or the early-2027 interim readout disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vertex Pharmaceuticals's 12-month outlook, with a consensus price target around $595.36 and implied upside of +15.6% versus the current price.
Average Target
$595.36
32 analysts
Implied Upside
+15.6%
vs. current price
Analyst Count
32
covering this stock
Price Range
$350 - $725
Analyst target range
Coverage is deep and overwhelmingly constructive: 28 analysts rate the stock, with 26 Buy, 5 Hold, and 1 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.625 (where 1.0 is a strong buy). The average target price of $595.36 implies roughly +10.5% upside from the $538.60 current price, a moderate but positive signal, and the consensus EPS estimate of $33.79 (range $32.23–$35.36) alongside average revenue estimates of $20.63B (range $19.90B–$21.37B) points to continued low-double-digit growth. The tone is bullish but not euphoric — the modest implied upside suggests much of the good news is already reflected.
The target range is wide, from a low of $350.00 to a high of $725.00, a spread of more than 2x that signals meaningful disagreement about the pipeline's value. The $725 high likely assumes multiple expansion plus successful diversification (Crinetics/acromegaly, APOL1 kidney, povetacicept, Journavx) and sustained CF dominance, while the $350 low prices in margin compression from rising R&D, CF competitive erosion, or pipeline failures. Institutional ratings are stable rather than trending — the November 3–4 cluster shows Barclays, Wells Fargo, JP Morgan, Morgan Stanley, and RBC all maintaining Overweight/Outperform, TD Cowen, UBS, and Goldman maintaining Buy, and Stifel holding at Hold — indicating conviction without fresh upgrades; the wide spread and uniform reiterations argue for position sizing that respects binary pipeline risk.
Bulls vs Bears: VRTX Investment Factors
The bull case currently has stronger evidence: a monopoly CF franchise throwing off $3.2B in TTM free cash flow, a fortress balance sheet (D/E 0.109), 26 of 28 analysts at Buy, and relative strength of +21.13 versus SPY over six months all point to a high-quality compounder in an orderly uptrend. The bear case rests less on the business than on the price and the P&L trajectory — Q3 net margin collapsed to 18.99% from 32.99% in Q2 as R&D rose to $1.321B, revenue growth has decelerated to 11.85%, and a 29x trailing PE embeds successful diversification. The single most important tension is whether the Q3 R&D step-up is a temporary Crinetics integration cost or a new baseline: if margins normalize back toward the mid-30s, the 27x forward multiple looks cheap and the stock re-rates toward the $595–$725 range; if spend stays elevated while CF growth stays low-double-digit, the premium compresses and the $350 bear target becomes live. Secondary but material is the binary pipeline calendar — APOL1 kidney interim data in early 2027 and povetacicept — which is the swing factor between the wide analyst targets.
Bullish
- CF monopoly funds self-financed expansion: Trikafta/Kaftrio ($2.437B) and Alyftrek ($705.8M) together drove the vast majority of Q3's $3.441B revenue, giving Vertex near-100% share and pricing power in cystic fibrosis. That franchise generated $3.202B of trailing free cash flow against debt-to-equity of just 0.109, so the diversification push into Crinetics, APOL1 kidney, povetacicept and Journavx is funded internally without dilution.
- Analyst consensus firmly constructive: 26 of 28 covering analysts rate VRTX a Buy (5 Hold, 1 Sell), producing a recommendation mean of 1.625 and an average target of $595.36 — roughly +10.5% upside from $538.60. The November 3–4 cluster of reiterations from Barclays, Wells Fargo, JP Morgan, Morgan Stanley, RBC, TD Cowen, UBS and Goldman shows conviction is stable, not eroding.
- Relative strength leadership versus SPY: VRTX is up 8.04% over the past month while SPY fell 2.26% (relative strength +10.30) and up 23.26% over six months versus SPY's 2.13% (+21.13 relative). The stock sits at ~80.8% of its $412.27–$568.67 52-week range with a max drawdown of only 15.21%, indicating an orderly uptrend of higher lows rather than a speculative spike.
- Pipeline catalysts with binary upside: Positive Phase II APOL1 kidney data (September 2026) and the ~$10B Crinetics acquisition — which management and press frame as adding over $5B in peak revenue from hormone disorders/acromegaly — create new growth engines beyond CF. Interim Phase II/III kidney results expected in early 2027 are a discrete, dated catalyst that the $725 high analyst target likely capitalizes.
Bearish
- Earnings compression from R&D step-up: Q3 net income fell to $653.6M (18.99% net margin) from $1.100B (32.99%) in Q2 and $1.031B (34.53%) in Q1, as R&D jumped to $1.321B from $994M sequentially. Operating income dropped to $712.9M (20.72% margin) from $1.247B (37.41%), so the question is whether this is temporary integration cost or a permanently higher spend baseline.
- Revenue growth decelerating to low-double-digits: Q3 revenue grew 11.85% YoY to $3.441B versus $3.076B a year earlier — well below the 20%+ growth Vertex historically posted. With CF already near saturation and diversification assets (Casgevy, Journavx, Palsonify) still immaterial contributors, the top-line trajectory depends on pipeline readouts rather than the base business.
- Extreme revenue concentration in CF: Trikafta/Kaftrio plus Alyftrek account for the overwhelming majority of quarterly revenue, with all other manufactured products at just $130.5M. Any CF pricing pressure, reimbursement change, or a future competitor success would hit the earnings base directly — the Sionna trial failure removes near-term threat but does not eliminate long-run competitive risk.
- Valuation premium leaves little room for error: At 29.32x trailing and 27.04x forward PE, VRTX trades at roughly a 30–45% premium to a typical large-cap biotech sector PE in the high-teens to low-20s, with PS of 9.60x and EV/EBITDA of 23.19x. The premium is defensible on 85% gross margins, but it means pipeline disappointments would compress the multiple as well as the earnings.
VRTX Technical Analysis
Vertex is in a sustained, orderly uptrend: the stock is up 23.95% over the trailing year and 19.13% year-to-date, and at $538.60 it sits at roughly 80.8% of its 52-week range of $412.27–$568.67 (about $30 below the high and $126 above the low). That positioning signals healthy momentum rather than overextension — the stock is neither pinned at highs nor broken down — and the 15.21% max drawdown confirms a trend of higher lows rather than a falling-knife profile. The 23.26% six-month gain versus a 2.13% SPY return (relative strength +21.13) underscores that this is leadership, not beta-driven drift.
Short-term momentum is accelerating and, importantly, diverging positively from the market: the stock is up 8.04% over the past month against a -2.26% SPY decline (relative strength +10.30), and up 6.50% over three months versus -2.83% for SPY (+9.33 relative). The 1-month gain outpaces the 3-month gain, indicating re-acceleration into the Q3 print (revenue $3.44B, +11.85% YoY) and the post-earnings drift toward the $558.88 October 30 close. The lone caution is the most recent tape: the stock slipped 0.74% on the latest session to $538.60 from a $542.62 prior close, and the 1-year relative strength (+11.68) is smaller than the 6-month figure, hinting the sharpest outperformance occurred in the spring-to-summer leg rather than right now.
Key technical levels are well defined: resistance sits at the $568.67 52-week high, with a secondary shelf near $558–$560 (the October 30 spike high); support rests at the $412.27 52-week low, with intermediate support around $485–$500 where the stock consolidated in July and mid-October. A breakout above $568.67 would confirm the multi-month uptrend and likely invite momentum buyers, while a breakdown below $500 would break the sequence of higher lows and flag trend deterioration. Volatility is remarkably low for a biotech — beta of just 0.28 versus the market means roughly 72% less volatility than SPY, which supports larger position sizing for risk-budgeted portfolios but also implies the stock will lag in sharp risk-on rallies; the 3.55 short ratio is unremarkable and offers no squeeze dynamic.
Beta
0.28
0.28x market volatility
Max Drawdown
-15.2%
Largest decline past year
52-Week Range
$412-$569
Price range past year
Annual Return
+22.0%
Cumulative gain past year
| Period | VRTX Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | -9.7% |
| 3m | -6.0% | -9.9% |
| 6m | +18.5% | -7.5% |
| 1y | +22.0% | +4.7% |
| ytd | +13.9% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRTX Fundamental Analysis
Revenue is growing steadily but decelerating at the margin: Q3 2026 revenue of $3.441B rose 11.85% YoY versus $3.076B in Q3 2025, and the sequential cadence ($2.987B in Q1, $3.334B in Q2, $3.441B in Q3) shows consistent expansion, though the YoY rate is more modest than the 20%+ growth Vertex historically posted. The franchise remains concentrated — Trikafta/Kaftrio contributed $2.437B and Alyftrek $705.8M of the quarter, with other manufactured product at $130.5M — meaning CF still drives the overwhelming majority of revenue and the diversification thesis (Casgevy, Journavx, Palsonify, Crinetics) is a future-growth option rather than a current earnings contributor. The trajectory implies low-double-digit top-line growth near term, with pipeline readouts (APOL1 kidney, povetacicept, T1D) as the swing factor for the next leg.
Profitability remains elite but is compressing: Q3 net income was $653.6M (net margin 18.99%) on gross profit of $2.915B (gross margin 84.71%), down sharply from Q2's $1.100B net income (32.99% margin) and Q1's $1.031B (34.53% margin). The compression is cost-driven, not demand-driven — R&D jumped to $1.321B in Q3 from $994M in Q2 and $962M in Q1, and operating income fell to $712.9M (20.72% operating margin) from $1.247B (37.41%) in Q2, reflecting the Crinetics integration and pipeline spend. Gross margin has drifted from 86.85% in Q1 to 84.71% in Q3, still far above typical large-cap biotech levels and consistent with Vertex's premium pricing power, but the earnings trajectory now depends on whether the R&D step-up is a temporary integration cost or a new baseline.
Financial health is fortress-like: debt-to-equity is just 0.109, current ratio 2.90, and trailing free cash flow is $3.202B, with Q3 FCF of $545.8M after $97.3M capex and a $9.063B acquisition outflow that was funded largely by $4.497B of debt repayment activity and investment maturities rather than distress. ROE of 21.18% and ROA of 10.62% confirm high-quality capital returns, and cash of $4.989B plus a 2.90x current ratio means Vertex can self-fund its pipeline without dilution. The one blemish is the Q3 FCF dip (from $1.013B in Q2 and $1.295B in Q1) tied to working-capital swings and the acquisition, but with $3.2B TTM FCF and negligible leverage, financial risk is minimal.
Quarterly Revenue
$3.4B
2026-09
Revenue YoY Growth
+11.8%
YoY Comparison
Gross Margin
84.7%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRTX Overvalued?
Because Vertex is solidly profitable (Q3 net income $653.6M, TTM positive), the PE ratio is the appropriate primary metric; the trailing PE of 29.32x versus a forward PE of 27.04x implies only modest earnings growth is priced in, a relatively narrow 8% compression that suggests the market is not extrapolating aggressive acceleration. The PEG ratio of -0.035 is not meaningful given the sign distortion from near-term earnings volatility, so the more informative read is the forward multiple of 27x against a 32.7% net margin and 85.0% gross margin — a quality-adjusted multiple that looks reasonable rather than stretched.
On peer comparison, Vertex trades at a premium to the broad biotechnology sector on most measures: PS of 9.60x, EV/Sales of 10.56x, EV/EBITDA of 23.19x, and P/B of 6.21x, with a trailing PE of 29.32x. Against a typical large-cap biotech sector PE in the high-teens to low-20s, Vertex's 29x represents roughly a 30–45% premium, which is defensible given its 85% gross margin, 21.2% ROE, and monopoly-like CF position — but the premium leaves less room for pipeline disappointments. The forward PE of 27.04x versus the sector's mid-20s forward average is a much narrower spread, suggesting the premium is concentrated in trailing earnings and should compress as growth materializes.
Historically, Vertex's own PE band has ranged from roughly 18x (Q4 2021) to 50.7x (Q3 2026, distorted by the earnings dip), with most quarters in the 22–29x zone; the current 29.32x trailing sits near the upper-middle of that band, while the 27.04x forward is closer to the middle. The PS ratio of 9.60x is well below the 32–46x historical PS readings from 2022–2025, but that comparison is distorted by share-count and revenue-base changes, so the PE is the cleaner anchor. Net-net, valuation is fair-to-slightly-rich versus history, pricing in successful diversification but not euphoria.
PE
29.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 18x~29x
vs. Industry Avg
29.3x
Industry PE ~29.3x*
EV/EBITDA
25.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the earnings trajectory rather than solvency. Q3 net income of $653.6M (18.99% margin) fell from $1.100B (32.99%) in Q2 as R&D rose to $1.321B from $993.8M and operating income dropped to $712.9M (20.72% margin) from $1.247B (37.41%); if this spend level is a new baseline rather than Crinetics integration noise, forward EPS of $33.79 could prove optimistic. Revenue concentration is acute — Trikafta/Kaftrio ($2.437B) and Alyftrek ($705.8M) dominate the $3.441B quarter while all other products contributed just $130.5M — so any CF pricing or reimbursement shock hits nearly the entire revenue base. Offsetting this, debt-to-equity of 0.109, a 2.90 current ratio, $4.989B cash and $3.202B TTM free cash flow mean there is no liquidity or leverage risk; the Q3 FCF dip to $545.8M reflects the $9.063B acquisition outflow and working capital, not operational distress. Market and competitive risks are primarily valuation and event-driven. At 29.32x trailing and 27.04x forward PE, PS of 9.60x and EV/EBITDA of 23.19x, VRTX carries roughly a 30–45% premium to the high-teens/low-20s large-cap biotech norm, leaving limited cushion if pipeline news disappoints. Beta of just 0.28 means low market correlation — protective in selloffs but a laggard in risk-on rallies — and the 3.55 short ratio offers no squeeze support. Competitive risk has eased near term after Sionna's CF trial failure and layoffs (September 2026), reinforcing the moat, but the $10B Crinetics integration, the Journavx non-opioid pain launch against entrenched generic opioids, and CRISPR's Casgevy momentum all require execution; regulatory and reimbursement decisions on new categories are outside Vertex's control. The worst-case scenario is a margin-reset plus pipeline-delay combination: Q3's R&D step-up proves structural, CF growth stays near 11–12%, and the early-2027 APOL1 kidney interim data or povetacicept readout disappoints, forcing analysts toward the $350 low target. From $538.60, that represents roughly -35%, and a retest of the $412.27 52-week low would be about -23.5%; the observed max drawdown of 15.21% understates event risk because it captures only the trailing period. A more moderate adverse path — multiple compression to the low-20s forward PE on unchanged $33.79 EPS — implies roughly $675–$710 fair value only if growth reaccelerates, but at 22x forward the stock would be near $495, about -8%, showing how sensitive the price is to the multiple rather than the earnings.
FAQ
The most severe risk is earnings compression from the R&D step-up: Q3 operating income fell to $712.9M (20.72% margin) from $1.247B (37.41%) in Q2 as R&D rose to $1.321B, and if that is a new baseline rather than Crinetics integration cost, the $33.79 consensus EPS is at risk. Second is revenue concentration — Trikafta/Kaftrio ($2.437B) and Alyftrek ($705.8M) dominate the $3.441B quarter while all other products contributed just $130.5M, so any CF pricing or reimbursement shock hits nearly the entire base. Third is binary pipeline risk: the early-2027 APOL1 kidney interim data and povetacicept readout explain the $350–$725 analyst target spread, and a failure would remove the optionality embedded in the 27x forward multiple. Fourth is valuation and macro sensitivity — at a 30–45% premium to sector PE with a beta of only 0.28, the stock offers little participation in risk-on rallies while remaining exposed to multiple compression if growth decelerates below 10%. Ranked by severity: margin reset first, pipeline binary second, CF concentration third, valuation compression fourth.
The 12-month forecast is anchored by three scenarios: a base case at 55% probability targeting $560–$620, a bull case at 25% targeting $650–$725, and a bear case at 20% targeting $350–$450. The base case is most likely and assumes revenue growth of 10–12% consistent with Q3's 11.85% and the $20.63B consensus, operating margin stabilizing in the high-20s to low-30s as Crinetics costs are absorbed, and the forward PE holding near 27x on $33.79 consensus EPS — which lands the stock near the $595.36 analyst average. The bull case requires Q4 operating margin back above 30% with R&D normalizing below $1.1B plus positive kidney or povetacicept data, while the bear case requires the R&D step-up to prove structural alongside a pipeline disappointment, pushing toward the $350 low target. The key assumption behind the base case is that the Q3 margin dip is temporary integration cost rather than a new spending baseline.
Vertex is fairly valued to modestly rich rather than cheap: the trailing PE of 29.32x and forward PE of 27.04x sit near the upper-middle of its own 22–29x historical band, and represent roughly a 30–45% premium to a typical large-cap biotech PE in the high-teens to low-20s. That premium is supported by an 84.71% Q3 gross margin, a 32.7% TTM net margin and 21.18% ROE, which are well above sector norms, and by PS of 9.60x and EV/EBITDA of 23.19x that are high in absolute terms but not extreme for a franchise with monopoly pricing power. The narrow 8% gap between trailing and forward PE implies the market is pricing only modest earnings growth toward the $33.79 consensus EPS, not aggressive acceleration. What the valuation embeds is successful diversification — Crinetics' $5B+ peak-revenue contribution, APOL1 kidney and povetacicept optionality — so a pipeline disappointment would hit the multiple as well as the earnings. The PEG ratio of -0.035 is not analytically useful given sign distortion, so the forward multiple against quality metrics is the cleaner anchor.
From a risk/reward standpoint VRTX offers roughly +10.5% upside to the $595.36 analyst average target against a bear-case downside of about -35% to the $350 low target, a skew that is only attractive because the base case (55% probability, $560–$620) is the most likely outcome and the business is exceptionally durable. The downside is cushioned by $3.202B in TTM free cash flow, debt-to-equity of 0.109, a 2.90 current ratio and $4.989B of cash, so the bear case requires a genuine margin reset or pipeline failure rather than balance-sheet stress. The biggest single risk is that Q3 net margin fell to 18.99% from 32.99% in Q2 as R&D jumped to $1.321B, which would compress the 27.04x forward multiple if it proves structural. It is a good buy for patient investors with a 2–3 year horizon who size the position to absorb binary clinical risk, and a poor buy for anyone expecting near-term multiple expansion given the stock already sits at ~80.8% of its 52-week range. Accumulating on weakness toward the $485–$500 support zone improves the risk/reward materially versus buying at $538.60.
VRTX is structurally a long-term holding: it is a profitable, cash-generative franchise with $3.202B TTM free cash flow, a 21.18% ROE and negligible leverage, whose value depends on multi-year pipeline conversion (APOL1 kidney, povetacicept, Crinetics acromegaly, Journavx) rather than quarterly momentum. The beta of just 0.28 means roughly 72% less volatility than the market, which suits risk-budgeted portfolios but makes it a poor short-term trading vehicle — there is no squeeze dynamic at a 3.55 short ratio and no dividend (payout ratio 0) to support income-oriented holding. Earnings visibility is high for the CF base but low for the pipeline, and the binary early-2027 readouts mean the thesis needs time to play out. A concrete minimum holding period of 24–36 months is appropriate, spanning at least two Q4 prints and the early-2027 kidney interim data, with position sizing that reflects the $350–$725 target dispersion. Short-term traders should note the stock is up 8.04% in a month versus SPY's -2.26%, so near-term mean reversion toward the $485–$500 support is a live risk.

